Home > Research Institute > Available Trials > Study of Carbo/Paclitaxel + INCMGA00012/Placebo in Squamous Cell Carcinoma of the Anal Canal
Study of Carbo/Paclitaxel + INCMGA00012/Placebo in Squamous Cell Carcinoma of the Anal Canal
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy
Disease Types: Gastrointestinal
Available at: Roanoke
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy
For More Information:
https://clinicaltrials.gov/ct2/show/NCT04472429?term=INCMGA00012%2FPlacebo&draw=2&rank=1